Compositions and methods of potentiating antimicrobials
AssigneeNeurothera Labs Inc.
InventorsEphraim Brener, Elran Haber, Adi Zuloff-Shani, Ascher Shmulewitz
Life of this patent
Estimating the term…
Abstract
Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.
Claims8
A method for treating or preventing a bacterial infection or bacterial biofilm comprising administering a therapeutically effective amount of a pharmaceutical composition comprising at least one anti-bacterial agent, at least one cannabinoid, and a pharmaceutically acceptable carrier,
- wherein a weight ratio between the at least one anti-bacterial agent and the at least one cannabinoid is between about 250:1 and about 1:50,
- wherein an anti-bacterial efficacy of the pharmaceutical composition is similar to, or better, than an anti-bacterial efficacy of a pharmaceutical composition comprising 2 to 150 times the amount of the at least one anti-bacterial agent without the at least one cannabinoid,
- wherein the at least one anti-bacterial agent comprises an aminoglycoside, wherein the aminoglycoside is gentamicin or a salt thereof,
- and
- wherein the at least one cannabinoid comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), or cannabigerol monomethyl ether (CBGM), a salt of any of the foregoing, or any combination thereof.
A method for treating or preventing a bacterial infection or a bacterial biofilm in a subject in need thereof, comprising administering to the subject a combination of a first pharmaceutical composition comprising at least one anti-bacterial agent and a second pharmaceutical composition comprising at least one cannabinoid wherein a weight ratio between the at least one anti-bacterial agent and the at least one cannabinoid is between about 250:1 and about 1:50,
- wherein the at least one anti-bacterial agent comprises an aminoglycoside, wherein the aminoglycoside is gentamicin or a salt thereof,
- wherein the at least one cannabinoid comprises tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG), cannabichromene (CBC), cannabicyclol (CBL), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), or cannabigerol monomethyl ether (CBGM), a salt of any of the foregoing, or any combination thereof, and
- wherein the combination has an anti-microbial efficacy similar to, or better than, the anti-microbial efficacy of the same first pharmaceutical composition comprising 2 to 150 times the amount of the anti-microbial agent without the second pharmaceutical composition comprising the at least one cannabinoid.
Dependencies are inferred from the claim text.